|
1
|
Howlader N, Noone AM, Krapcho M, Miller D,
Bishop K, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, et
al: SEER Cancer Statistics Review, 1975–2013. National Cancer
Institute; Bethesda, MD: https://seer.cancer.gov/csr/1975_2013/September
12–2016
|
|
2
|
Haugen BR, Alexander EK, Bible KC, Doherty
GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM,
Schlumberger M, et al: 2015 American Thyroid Association management
guidelines for adult patients with thyroid nodules and
differentiated thyroid cancer: The American Thyroid Association
guidelines task force on thyroid nodules and differentiated thyroid
cancer. Thyroid. 26:1–133. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Schwartz DL, Lobo MJ, Ang KK, Morrison WH,
Rosenthal DI, Ahamad A, Evans DB, Clayman G, Sherman SI and Garden
AS: Postoperative external beam radiotherapy for differentiated
thyroid cancer: Outcomes and morbidity with conformal treatment.
Int J Radiat Oncol Biol Phys. 74:1083–1091. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Terezakis SA, Lee KS, Ghossein RA, Rivera
M, Tuttle RM, Wolden SL, Zelefsky MJ, Wong RJ, Patel SG, Pfister
DG, et al: Role of external beam radiotherapy in patients with
advanced or recurrent nonanaplastic thyroid cancer: Memorial
Sloan-kettering cancer center experience. Int J Radiat Oncol Biol
Phys. 73:795–801. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gottlieb JA and Hill CS Jr: Chemotherapy
of thyroid cancer with adriamycin: Experience with 30 patients. N
Engl J Med. 290:193–197. 1974. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kim JH and Leeper RD: Combination
adriamycin and radiation therapy for locally advanced carcinoma of
the thyroid gland. Int J Radiat Oncol Biol Phys. 9:565–567. 1983.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kim JH and Leeper RD: Treatment of locally
advanced thyroid carcinoma with combination doxorubicin and
radiation therapy. Cancer. 60:2372–2375. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rosenthal CJ and Rotman M: Pilot study of
interaction of radiation therapy with doxorubicin by continuous
infusion. NCI Monogr. 285–290. 1988.PubMed/NCBI
|
|
9
|
Welsh JW, Komaki R, Amini A, Munsell MF,
Unger W, Allen PK, Chang JY, Wefel JS, McGovern SL, Garland LL, et
al: Phase II trial of erlotinib plus concurrent whole-brain
radiation therapy for patients with brain metastases from
non-small-cell lung cancer. J Clin Oncol. 31:895–902. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sano D, Matsumoto F, Valdecanas DR, Zhao
M, Molkentine DP, Takahashi Y, Hanna EY, Papadimitrakopoulou V,
Heymach J, Milas L and Myers JN: Vandetanib restores head and neck
squamous cell carcinoma cells' sensitivity to cisplatin and
radiation in vivo and in vitro. Clin Cancer Res.
17:1815–1827. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Brose MS, Nutting CM, Jarzab B, Elisei R,
Siena S, Bastholt L, de la Fouchardiere C, Pacini F, Paschke R,
Shong YK, et al: Sorafenib in radioactive iodine-refractory,
locally advanced or metastatic differentiated thyroid cancer: A
randomised, double-blind, phase 3 trial. Lancet. 384:319–328. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Capdevila J, Iglesias L, Halperin I,
Segura A, Martínez-Trufero J, Vaz MÁ, Corral J, Obiols G, Grande E,
Grau JJ and Tabernero J: Sorafenib in metastatic thyroid cancer.
Endocr Relat Cancer. 19:209–216. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pacini F, Castagna MG, Brilli L and
Pentheroudakis G: ESMO Guidelines Working Group: Thyroid cancer:
ESMO clinical practice guidelines for diagnosis, treatment and
follow-up. Ann Oncol. 23 Suppl 7:vii110–vii119. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sherman EJ, Lim SH, Ho AL, Ghossein RA,
Fury MG, Shaha AR, Rivera M, Lin O, Wolden S, Lee NY and Pfister
DG: Concurrent doxorubicin and radiotherapy for anaplastic thyroid
cancer: A critical re-evaluation including uniform pathologic
review. Radiother Oncol. 101:425–430. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Brierley J and Sherman E: The role of
external beam radiation and targeted therapy in thyroid cancer.
Semin Radiat Oncol. 22:254–262. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lee CG, Heijn M, de Tomasso E,
Griffon-Etienne G, Ancukiewicz M, Koike C, Park KR, Ferrara N, Jain
RK, Suit HD and Boucher Y: Anti-Vascular endothelial growth factor
treatment augments tumor radiation response under normoxic or
hypoxic conditions. Cancer Res. 60:5565–5570. 2000.PubMed/NCBI
|
|
18
|
Murray L, Longo J, Wan J, Chung C, Wang L,
Dawson L, Milosevic M, Oza A and Brade A: Phase I dose escalation
study of concurrent palliative radiation therapy with sorafenib in
three anatomical cohorts (Thorax, Abdomen, Pelvis): The TAP study.
Radiather Oncol. 124:74–79. 2017. View Article : Google Scholar
|
